Biohaven .(US:BHVN) Globenewswire·2025-09-12 14:00Core Points - Rosen Law Firm is reminding investors who purchased Biohaven Ltd. securities between March 24, 2023, and May 14, 2025, of the September 12, 2025, lead plaintiff deadline for a class action lawsuit [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] Company Information - Biohaven Ltd. is facing a class action lawsuit due to allegations of false and misleading statements regarding its drug candidates, including the overstated regulatory prospects of troriluzole for spinocerebellar ataxia and BHV-7000 for bipolar disorder [4] - The lawsuit claims that the true details about the efficacy and regulatory prospects of these treatments, once revealed, are likely to have a significant negative impact on Biohaven's business and financial condition [4] Legal Process - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2][5] - Investors wishing to serve as lead plaintiff must file a motion with the court by September 12, 2025 [2] - No class has been certified yet, meaning investors are not represented by counsel unless they retain one [6]